Final overall survival data for PEACE-3 (NCT02194842) evaluating the combination of enzalutamide (Xtandi) and radium-223 ...

Anticipated findings from the LITESPARK-011 trial (NCT04586231) to be presented during the 2026 ASCO Genitourinary Cancers ...

In an interview with Targeted Oncology, Paolo Strati, MD, associate professor in the Department of Lymphoma/Myeloma in the ...

AI accelerates precision oncology, turning genomic data into smarter, targeted cancer treatments, fewer adverse effects, and faster decisions for personalized care. Chadi Nabhan, MD, MBA, FACP, ...

In an analysis of therapeutic interventions following the failure of chimeric antigen receptor (CAR) T-cell therapy, Rahul ...

Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 ...

Dr Parikh explained that KEYNOTE-B15 (NCT04700124) is evaluating the role of perioperative enfortumab vedotin (Padcev), an ...

Central to this evolution is RB-1355, a novel therapeutic comprised of autologous macrophages. Derived from a patient’s own ...

During a live event, Daniel Olson, MD, discussed data and experience using tumor-infiltrating lymphocytes in melanoma.

The MajesTEC-1 trial (NCT04557098) 1,2 focusing on the bispecific antibody teclistamab (Tecvayli), stands as a landmark study in this space. Conducted during the unique logistical and clinical ...

Rahul Parikh, MD, a professor of medicine at the University of Kansas (KU) Medical Center, discussed the critical role of ...

The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival ...